Activation of AMPK by Bitter Melon Triterpenoids Involves CaMKKβ

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Iseli, Tristan J ^a   Turner, Nigel ^a   Zeng, Xiao Yi ^a,b   Cooney, Gregory J ^a   Kraegen, Edward W ^a   Yao, Sheng ^c   Ye, Yang ^c   James, David E ^a   Ye, Ji Ming ^a,b,c  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b RMIT UNIVERSITY   (Australia)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; CALCIUM ION; GLUCOSE TRANSPORTER 4; TRITERPENOID; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN; TERPENE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL RESPIRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; IN VITRO STUDY; MOLECULAR DYNAMICS; MOMORDICA CHARANTIA; PROTEIN BINDING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; CHEMISTRY; DEFICIENCY; DRUG EFFECTS; HELA CELL LINE; HUMAN; METABOLISM; PHOSPHORYLATION;

CUCUMIS;

AMP-ACTIVATED PROTEIN KINASES; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; ENZYME ACTIVATION; HELA CELLS; HUMANS; HYPOGLYCEMIC AGENTS; MOMORDICA CHARANTIA; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TERPENES;

EID: 84876710974     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062309     Document Type: Article

References (46)

1. Shaw JE, Sicree RA, Zimmet PZ, (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14.
2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, et al. (2010) Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 293-301.
3. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, et al. (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147: 386-399.
4. Fuangchan A, Sonthisombat P, Seubnukarn T, Chanouan R, Chotchaisuwat P, et al. (2011) Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol 134: 422-428.
5. Day C, Cartwright T, Provost J, Bailey CJ, (1990) Hypoglycaemic effect of Momordica charantia extracts. Planta Med 56: 426-429.
6. Chaturvedi P, George S, (2010) Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. J Med Food 13: 520-527.
7. Wang ZQ, Zhang XH, Yu Y, Poulev A, Ribnicky D, et al. (2011) Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice. J Nutr Biochem 22: 1064-1073.
8. Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, et al. (2008) Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 15: 263-273.
9. Zeng XY, Wang YP, Cantley J, Iseli TJ, Molero JC, et al. (2012) Oleanolic acid reduces hyperglycemia beyond treatment period with Akt/FoxO1-induced suppression of hepatic gluconeogenesis in type-2 diabetic mice. PLoS One 7: e42115.
10. Steinberg GR, Kemp BE, (2009) AMPK in Health and Disease. Physiol Rev 89: 1025-1078.
11. Cool B, Zinker B, Chiou W, Kifle L, Cao N, et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3: 403-416.
12. Iglesias MA, Furler SM, Cooney GJ, Kraegen EW, Ye JM, (2004) AMP-activated protein kinase activation by AICAR increases both muscle fatty acid and glucose uptake in white muscle of insulin-resistant rats in vivo. Diabetes 53: 1649-1654.
13. Moller DE, (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827.
14. Nissen SE, Wolski K, (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
15. Turner N, Li JY, Gosby A, To SW, Cheng Z, et al. (2008) Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57: 1414-1418.
16. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, et al. (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256-2264.
17. Zini R, Morin C, Bertelli A, Bertelli AA, Tillement JP, (1999) Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res 25: 87-97.
18. Yin J, Gao Z, Liu D, Liu Z, Ye J, (2008) Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 294: E148-156.
19. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752.
20. Iseli TJ, Walter M, van Denderen BJ, Katsis F, Witters LA, et al. (2005) AMP-activated protein kinase beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186-270). J Biol Chem 280: 13395-13400.
21. Scott JW, Hawley SA, Green KA, Anis M, Stewart G, et al. (2004) CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 113: 274-284.
22. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, et al. (2011) Structure of mammalian AMPK and its regulation by ADP. Nature 472: 230-233.
23. Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, et al. (2011) AMPK is a direct adenylate charge-regulated protein kinase. Science 332: 1433-1435.
24. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, et al. (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2: 28.
25. Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, et al. (2005) The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 280: 29060-29066.
26. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, et al. (2005) Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2: 21-33.
27. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM, (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326: 1707-1711.
28. Green MF, Anderson KA, Means AR, (2011) Characterization of the CaMKKbeta-AMPK signaling complex. Cell Signal 23: 2005-2012.
29. Green MF, Scott JW, Steel R, Oakhill JS, Kemp BE, et al. (2011) Ca2+/Calmodulin-dependent protein kinase kinase beta is regulated by multisite phosphorylation. J Biol Chem 286: 28066-28079.
30. Iseli TJ, Oakhill JS, Bailey MF, Wee S, Walter M, et al. (2008) AMP-activated protein kinase subunit interactions: beta1:gamma1 association requires beta1 Thr-263 and Tyr-267. J Biol Chem 283: 4799-4807.
31. Goransson O, McBride A, Hawley SA, Ross FA, Shpiro N, et al. (2007) Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 282: 32549-32560.
32. Scott JW, van Denderen BJ, Jorgensen SB, Honeyman JE, Steinberg GR, et al. (2008) Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol 15: 1220-1230.
33. Salt I, Celler JW, Hawley SA, Prescott A, Woods A, et al. (1998) AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J 334 (Pt 1): 177-187.
34. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, et al. (2005) Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2: 9-19.
35. Hardie DG, (1999) Roles of the AMP-activated/SNF1 protein kinase family in the response to cellular stress. Biochem Soc Symp 64: 13-27.
36. Fogarty S, Hawley SA, Green KA, Saner N, Mustard KJ, et al. (2010) Calmodulin-dependent protein kinase kinase-beta activates AMPK without forming a stable complex: synergistic effects of Ca2+ and AMP. Biochem J 426: 109-118.
37. Soderling TR, (1999) The Ca-calmodulin-dependent protein kinase cascade. Trends Biochem Sci 24: 232-236.
38. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, et al. (2008) A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133: 462-474.
39. Zhu YJ, Li CP, Tang WY, Li AP, Liu QZ, et al. (2007) Single nucleotide polymorphism of the JWA gene is associated with risk of leukemia: a case-control study in a Chinese population. J Toxicol Environ Health A 70: 895-900.
40. Hsu C, Hsieh CL, Kuo YH, Huang CJ, (2011) Isolation and identification of cucurbitane-type triterpenoids with partial agonist/antagonist potential for estrogen receptors from Momordica charantia. J Agric Food Chem 59: 4553-4561.
41. Hwang YP, Kim HG, Hien TT, Jeong MH, Jeong TC, et al. (2011) Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase. Toxicol Appl Pharmacol 257: 48-58.
42. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr, (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660.
43. Balhuizen A, Kumar R, Amisten S, Lundquist I, Salehi A, (2010) Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Mol Cell Endocrinol 320: 16-24.
44. Liby KT, Yore MM, Sporn MB, (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369.
45. Chen X, Lou G, Meng Z, Huang W, (2011) TGR5: a novel target for weight maintenance and glucose metabolism. Exp Diabetes Res 2011: 853501.
46. Anderson KA, Means RL, Huang QH, Kemp BE, Goldstein EG, et al. (1998) Components of a calmodulin-dependent protein kinase cascade. Molecular cloning, functional characterization and cellular localization of Ca2+/calmodulin-dependent protein kinase kinase beta. J Biol Chem 273: 31880-31889.